132 related articles for article (PubMed ID: 19150497)
1. Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine.
von Kleist M; Huisinga W
Eur J Pharm Sci; 2009 Mar; 36(4-5):532-43. PubMed ID: 19150497
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors.
Olivero OA
Environ Mol Mutagen; 2007; 48(3-4):215-23. PubMed ID: 16395695
[TBL] [Abstract][Full Text] [Related]
3. 5'-aminocarbonyl phosphonates as new zidovudine depot forms: antiviral properties, intracellular transformations, and pharmacokinetic parameters.
Khandazhinskaya AL; Yanvarev DV; Jasko MV; Shipitsin AV; Khalizev VA; Shram SI; Skoblov YS; Shirokova EA; Kukhanova MK
Drug Metab Dispos; 2009 Mar; 37(3):494-501. PubMed ID: 19106116
[TBL] [Abstract][Full Text] [Related]
4. Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver.
Desai VG; Lee T; Delongchamp RR; Leakey JE; Lewis SM; Lee F; Moland CL; Branham WS; Fuscoe JC
Mitochondrion; 2008 Mar; 8(2):181-95. PubMed ID: 18313992
[TBL] [Abstract][Full Text] [Related]
5. Plasma and cellular markers of 3'-azido-3'-dideoxythymidine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs.
Meng Q; Olivero OA; Fasco MJ; Bellisario R; Kaminsky L; Pass KA; Wade NA; Abrams EJ; Nesel CJ; Ness RB; Bigbee WL; O'Neill JP; Walker DM; Poirier MC; Walker VE
Environ Mol Mutagen; 2007; 48(3-4):307-21. PubMed ID: 17358024
[TBL] [Abstract][Full Text] [Related]
6. 3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes.
Purcet S; Minuesa G; Molina-Arcas M; Erkizia I; Casado FJ; Clotet B; Martinez-Picado J; Pastor-Anglada M
Antivir Ther; 2006; 11(6):803-11. PubMed ID: 17310825
[TBL] [Abstract][Full Text] [Related]
7. Frequency of Hprt mutant lymphocytes and micronucleated erythrocytes in p53-haplodeficient mice treated perinatally with AZT and AZT in combination with 3TC.
Dobrovolsky VN; Shaddock JG; Mittelstaedt RA; Bishop ME; Lewis SM; Lee FW; Aidoo A; Leakey JE; Dunnick JK; Heflich RH
Environ Mol Mutagen; 2007; 48(3-4):270-82. PubMed ID: 17358030
[TBL] [Abstract][Full Text] [Related]
8. Low-dose, sublingual AZT-monophosphate therapy for HIV+ patients?
Johnson S
Med Hypotheses; 2001 Mar; 56(3):409-10. PubMed ID: 11359372
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of zidovudine uptake by dehydroepiandrosterone sulfate in rat syncytiotrophoblast cell line TR-TBT 18d-1.
Nishimura T; Seki Y; Sato K; Chishu T; Kose N; Terasaki T; Kang YS; Sai Y; Nakashima E
Drug Metab Dispos; 2008 Oct; 36(10):2080-5. PubMed ID: 18653745
[TBL] [Abstract][Full Text] [Related]
10. Effect of short-term exposure to zidovudine (AZT) on the expression of mitochondria-related genes in skeletal muscle of neonatal mice.
Desai VG; Lee T; Moland CL; Branham WS; Von Tungeln LS; Beland FA; Fuscoe JC
Mitochondrion; 2009 Feb; 9(1):9-16. PubMed ID: 18824140
[TBL] [Abstract][Full Text] [Related]
11. A critical analysis of the pharmacology of AZT and its use in AIDS.
Papadopulos-Eleopulos E; Turner VF; Papadimitriou JM; Causer D; Alphonso H; Miller T
Curr Med Res Opin; 1999; 15 Suppl 1():S1-45. PubMed ID: 11594171
[TBL] [Abstract][Full Text] [Related]
12. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
[TBL] [Abstract][Full Text] [Related]
13. In vivo tissue disposition of 3'-azido-3'-deoxythymidine and its anabolites in control and retrovirus-infected mice.
Chow HH; Li P; Brookshier G; Tang Y
Drug Metab Dispos; 1997 Apr; 25(4):412-22. PubMed ID: 9107539
[TBL] [Abstract][Full Text] [Related]
14. Development of a stochastic model for the efficacy of NRTIs using known mechanisms of action.
Khalili S; Monaco JM; Armaou A
J Theor Biol; 2010 Aug; 265(4):704-17. PubMed ID: 20510251
[TBL] [Abstract][Full Text] [Related]
15. Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications.
Kayitare E; Vervaet C; Ntawukulilyayo JD; Seminega B; Bortel V; Remon JP
Int J Pharm; 2009 Mar; 370(1-2):41-6. PubMed ID: 19059324
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine.
Quevedo MA; Briñón MC
Antiviral Res; 2009 Aug; 83(2):103-11. PubMed ID: 19549583
[TBL] [Abstract][Full Text] [Related]
17. Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.
Vela JE; Miller MD; Rhodes GR; Ray AS
Antivir Ther; 2008; 13(6):789-97. PubMed ID: 18839780
[TBL] [Abstract][Full Text] [Related]
18. The excision mechanism in reverse transcriptase: pyrophosphate leaving and fingers opening are uncoupled events with the analogues AZT and d4T.
Carvalho AT; Fernandes PA; Ramos MJ
J Phys Chem B; 2007 Oct; 111(41):12032-9. PubMed ID: 17887788
[TBL] [Abstract][Full Text] [Related]
19. The nucleoside reverse transcriptase inhibitors didanosine, lamivudine, stavudine and zidovudine show little effect on the virulence of Candida albicans in vitro.
Ahmadou Ahidjo B; Veale R; Dusé AG; Becker P; Marais E
Int J Antimicrob Agents; 2008 Aug; 32(2):186-91. PubMed ID: 18571385
[TBL] [Abstract][Full Text] [Related]
20. Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages.
Hillaireau H; Le Doan T; Appel M; Couvreur P
J Control Release; 2006 Dec; 116(3):346-52. PubMed ID: 17113178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
